Form 4: Benitec COO Granted 500,000 Stock Options

Benitec Biopharma's Chief Operating Officer, Sophie Mukadam, was granted 500,000 stock options with an exercise price of $13.53.

Summary

• Sophie Mukadam, Chief Operating Officer of Benitec Biopharma Inc. (BNTC), was granted 500,000 stock options.
• The options have an exercise price of $13.53 per share.
• The grant date for these options was November 18, 2025.
• The options will expire on November 18, 2035.
• Vesting will occur in 16 substantially equal quarterly installments, beginning on March 31, 2026.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally viewed as a positive for aligning management incentives with shareholder interests, though it does not provide direct financial performance data.

Positives

• The grant of 500,000 stock options to the Chief Operating Officer aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive for value creation.

Negatives

• No direct negative information is presented in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The vesting schedule, commencing March 31, 2026, and extending over 16 quarterly installments, indicates a long-term commitment and incentive structure for the Chief Operating Officer to contribute to the company's future performance.

Industry Context

This stock option grant is a standard practice in executive compensation within the biotechnology and pharmaceutical industries, designed to attract, retain, and motivate key executives by linking their personal financial success to the long-term performance of the company's stock.

Stakeholder Impact

• Shareholders: Potential for increased alignment between executive incentives and shareholder value creation.
• Employees: May signal confidence in the company's future, potentially boosting morale.

Next Steps

• The stock options will begin vesting in 16 substantially equal quarterly installments starting March 31, 2026.

Key Dates

Keywords

Benitec Biopharma, BNTC, Sophie Mukadam, Chief Operating Officer, Stock Options, Insider Transaction, Executive Compensation, Form 4, Equity Grant